$78.03
Today
as of Jul 22, 16:49 ET
Last 30 days
Recent Press Releases & News
HAE: Lowering target price to $78.00
Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
Overview
52-week range
$47
$87
77% of range
Avg surprise (last 3)
+3.8%
Avg reaction (last 2)
+4.5%
100% positive
Latest IV / EM
66%
EM ±15.1% · $80 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $1.29 | $1.28 | +0.8% | +4.0% | +3.2% | earnings |
| Sat Dec 27, 2025 | Dec 2025 | $0.95 | — | — | — | — | financials |
| Sat Sep 27, 2025 | Sep 2025 | $0.81 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $1.10 | $1.01 | +8.9% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $1.24 | $1.22 | +1.6% | — | +5.9% | earnings |
| Sat Dec 28, 2024 | Dec 2024 | $0.74 | — | — | — | — | financials |
| Sat Sep 28, 2024 | Sep 2024 | $0.66 | — | — | — | — | financials |
| Sat Jun 29, 2024 | Jun 2024 | $0.74 | — | — | — | — | financials |
| Sat Dec 30, 2023 | Dec 2023 | $0.61 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.48 | — | — | — | — | financials |
| Sat Jul 1, 2023 | Jul 2023 | $0.80 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | BMO | $1.07 | $1.10 | -2.7% |
Financials
Income statement (quarterly)
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | $137M | $133M | $129M | — | $155M | $158M | $161M | — |
| Gross profit | $202M | $195M | $192M | — | $194M | $187M | $175M | — |
| Operating income | $67M | $58M | $54M | — | $59M | $52M | $40M | — |
| Net income | $45M | $39M | $34M | — | $37M | $34M | $38M | — |
| EPS (diluted) | $0.95 | $0.81 | $0.70 | — | $0.74 | $0.66 | $0.74 | — |
Balance sheet (quarterly)
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $363M | $296M | $293M | $307M | $321M | $299M | $344M | $179M |
| Inventory | $321M | $336M | $361M | $365M | $360M | $382M | $374M | $317M |
| Total current assets | $944M | $900M | $913M | $935M | $1.01B | $956M | $979M | $769M |
| Total assets | $2.49B | $2.44B | $2.46B | $2.45B | $2.53B | $2.53B | $2.54B | $2.20B |
| Long-term debt | $920M | $920M | $921M | $921M | $1.22B | $1.22B | $1.22B | $798M |
| Total liabilities | — | — | — | — | — | — | — | — |
| Total equity | $911M | $849M | $882M | $821M | $907M | $879M | $905M | $960M |